Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Placebo-controlled, double-blind, randomized trial of Adrecizumab in cardiogenic shock
2018-002824-17Phase 2Completed
- Sponsor
- University Medical Center Hamburg-Eppendorf
- Start
- Nov 2018
- Modality
- IgG Antibodies → Naked Antibodies → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in cardiogenic shock comparing Adrecizumab with Placebo (2 arms). Primary endpoint: Primary safety endpoints. Started Nov 2018; status: completed.
02
Drugs
adrecizumab
03
Conditions
cardiogenic shock
Beyond the preview
Go deeper on 2018-002824-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002824-17.